Track A2: Artificial Intelligence: Beyond the Hype, Into Implementations
Saturday, 27 September | 16:30–18:00 | Grand Ballroom (Level 4)
In recent years, there has been increasing hype over the potential of artificial intelligence (AI). This trend has been particularly fueled by the rapid development of generative AI technologies and tools, including ChatGPT, DeepSeek, and Gemini. While some industries have openly embraced the technology, the healthcare community remains cautious about fully adopting and incorporating these tools for widespread use. Issues such as AI transparency, responsibility for decisions made with the assistance of AI, and AI hallucinations continue to be debated within the industry.
This session showcases examples of AI implementation in healthcare, particularly in improving medication safety. Participants will learn about the considerations taken by the researchers and clinicians involved in the implementation. They will also hear opinions from thought leaders on existing issues and how we should move forward.
Presentations
NexRx.AI by Ms Justina Koi Li MA
This presentation introduces an artificial intelligence–driven project, NexRx.AI, designed to enhance medication safety in hospitalised patients with diabetes.
By leveraging machine learning algorithms to analyze 3 years of electronic medical records, the system aims to detect medication errors at prescribing stage and predict potential adverse drug reactions in the inpatient setting.
Artificial Intelligence–Driven Insights for Safer Patients and Medication Use by A/Prof Lita CHEW
Healthcare institutions face mounting challenges in reviewing medication error incidents, with established frameworks such as the human factors analysis and classification system (HFACS) and root cause analysis (RCA), often requiring intensive time and expert resources, and yielding inconsistent outcomes due to subjective human interpretation.
This presentation explores how a generative pre-trained transformer 4 (GPT-4)-based large language model (LLM) can be integrated into clinical incident review workflows. Attendees will learn how LLMs can process de-identified reports, align with HFACS and RCA frameworks, and deliver outputs rated highly for clarity, relevance, and contextual understanding. The discussion highlights the strengths of LLM-driven reviews in standardising outputs and expediting the analysis process, while candidly addressing the limitations, such as variability when input data is sparse and in imperfect alignment with expert consensus. Ethical considerations and the importance of human oversight are emphasised. This presentation offers valuable insights for healthcare leaders and risk managers considering responsible artificial-intelligence adoption as an augmentation, not a replacement, for expert-driven safety reviews.
What Does Validation Mean? by Dr Teck Chuan VOO
Artificial intelligence (AI) in healthcare needs to be “validated”, yet the term can mean different things to regulators, clinicians, and ethicists. This talk focuses on medication-related AI tools, to examine the different senses of validation, from accuracy to clinical outcomes. It will also consider how these understandings shape the benefits and limits of AI in augmenting clinical decision-making.
Aligning Innovators, Clinicians, and Regulators for the Adoption of Artifical Intelligence in Healthcare by Mr Ping Heng TONG
Innovators/Entrepreneurs have always been viewed with suspicion. This is natural, as innovators/entrepreneurs tend to disrupt habits and way of life for people and society at large.
Artificial intelligence will bring forth a wave of changes that will be very exciting for innovators/entrepreneurs – but it will be a major challenge for clinicians and regulators.
How can we come together as allies that will make healthcare “cheaper, better, and faster”? This is the question that this presentation aims to address.
Fireside Chat moderated by Dr Jasmine Chiat Ling ONG
Panelists:
• A/Prof Lita CHEW
• Ms Justina Koi Li MA
• Mr Ping Heng TONG
• Dr Teck Chuan VOO
Speakers and Moderator
Ms Justina Koi Li MA
Senior Principal Pharmacist
Pharmacy
Singapore General Hospital
Singapore
Ms Justina Koi Li Ma is a registered pharmacist with over 14 years of experience. At Singapore General Hospital (SGH), she served as second-in-charge of the Block 4 Level 1 outpatient pharmacy from 2019 to 2023, where she successfully led the hospital-wide transition to a paperless outpatient workflow in 2021.
She has also contributed to the training and development of future pharmacists, having been Chief Preceptor (2019–2021) and Chairperson of the PSS Pre-Registration Pharmacist Training Program in 2021. Since 2021, she has been part of the SPC Competency Standards Framework Review Workgroup.
Currently, she leads the innovation unit in SGH’s pharmacy division, spearheading cutting-edge projects, including Autonomous Mobile Robot implementation for medication delivery, applying Robotic Process Automation for various pharmacy workflows, and artificial-intelligence applications in medication-error detection. Her expertise is further evidenced by her long-standing certification as an ACC pharmacist (2010–2023) and her leadership in various committees, including the SingHealth Staff Engagement and Wellness workgroup (2021–2023).
A/Prof Lita CHEW
Group Chief Pharmacist
Group Pharmacy
SingHealth
Singapore
A/Prof Lita Chew is a distinguished healthcare leader and pharmacist with more than 30 years in Singapore’s public healthcare sector. As Group Chief Pharmacist at SingHealth, she drives the advancement of pharmacy practice and workforce integration across Singapore’s largest healthcare cluster. A/Prof Chew also serves as Director of Allied Health & Pharmacy at the National Cancer Centre Singapore and is an Associate Professor at the National University of Singapore. Her academic credentials include Bachelor of Science (Pharmacy) from NUS, Master in Medical Science (Clinical Oncology) from the University of Birmingham, Fellowship in Pharmacy Practice from the University of Illinois, and leadership training at Harvard Kennedy School. She is recognised for pioneering national pharmacy strategy, pharmacy specialisation, and leading innovative projects in digital health and sustainability. A/Prof Chew’s impact is further reflected in her leadership roles in professional councils, her extensive research, and numerous national awards.
Dr Teck Chuan VOO
Head
Office of Ethics in Healthcare
SingHealth
Singapore
Dr Teck Chuan Voo heads the Office of Ethics in Healthcare at SingHealth and chairs the SingHealth Ethics Network Council. A bioethicist with the SingHealth Duke-NUS Medical Humanities Institute, he contributes to its Bioethics and Health Professions Education programmes. He has published over 60 articles and book chapters, co-edited three books, and helped develop medical ethics education and ethics committee training in Singapore. He serves on several national and institutional ethics committees, including the Bioethics Advisory Committee and National Medical Ethics Committee. He is on the International Association of Bioethics Board of Directors and serves as its communication officer. He co-leads the Southeast Asia Bioethics Network and serves on ethics advisory boards for international biomedical research projects. He has contributed to the work of the World Health Organization in integrating ethics into clinical and public health guidelines and developing ethics guidance for research and for public health emergencies.
Mr Ping Heng TONG
CEO/Co-Founder
SmartRx Pte Ltd
Singapore
As a seasoned entrepreneur and healthcare innovator with over 36 years of experience across Asia, Mr Ping Heng Tong brings a unique blend of startup execution, market insight, and cross-border leadership. From founding SmartRx, a telemedicine venture integrating proprietary monitoring and dispensing systems, to transforming Aeras Medical into a connected health provider, he has consistently delivered scalable solutions in healthcare.
Dr Jasmine Chiat Ling ONG
Principal Clinical Pharmacist
Singapore General Hospital
Singapore
Dr Jasmine Ong is a critical care pharmacist at the Singapore General Hospital (SGH). She received her Doctor of Pharmacy (PharmD) degree in 2018 from the National University of Singapore (NUS) and board certification in critical care pharmacy (BCCCP, USA) in 2020. Her research interests include pharmacokinetics/pharmacodynamics of adult critically ill patients, as well as artificial intelligence (AI) and health technology innovation.
Dr Ong leads the SGH pharmacy in its AI innovation efforts and is appointed as an EXCO member in the SingHealth AI Office. She is also an appointed adjunct faculty with Duke-NUS Medical School. As a strong advocate for clinical innovation research, Dr Ong is the first pharmacist in Singapore to be awarded the National Medical Research Council (NMRC) Clinician Innovator Award and the AI Singapore Technology Challenge as the lead medical principal investigator. She has won accolades such as the SingHealth Young Discoverer Award (Allied Health) in recognition of her research and innovation pursuits and, most recently, the US-ASEAN Fulbright Visiting Scholarship for FY23/24.
